Expensify (EXFY) is drawing fresh attention after launching Expensify MCP, a new integration that lets AI assistants like ChatGPT and Claude query expense data in plain language directly from customer accounts.

That MCP launch comes as Expensify’s short term momentum has picked up, with a 30% 1 day share price return and an 86.89% 90 day share price return, even though the 1 year total shareholder return is down 30.04%.

If this AI driven move has your attention, it could be a good moment to see what other small AI players are doing and check out 63 profitable AI stocks that aren't just burning cash

With Expensify trading at US$1.56 after recent gains and analyst targets and intrinsic estimates sitting lower, the key question is whether the stock is still mispriced or whether the market is already factoring in future growth.

Most Popular Narrative: 39% Overvalued

Compared with the most followed fair value estimate of $1.13, Expensify’s last close at $1.56 sits well above what that narrative considers reasonable, and the gap is built on specific expectations about margins, multiples and discount rates.

The analysts have a consensus price target of $1.12 for Expensify based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $1.25, and the most bearish reporting a price target of just $1.0.

Curious what justifies that valuation cut alongside higher margin assumptions and a lower future P/E? The entire narrative rests on carefully tuned revenue declines, margin improvement and a specific discount rate, and the full set of assumptions is where the real story on Expensify starts to show.

Result: Fair Value of $1.13 (OVERVALUED)

However, Expensify still faces risks around ongoing losses and intense competition in AI driven expense tools, which could challenge both the growth story and the valuation case.

Another View on Expensify’s Valuation

While the analyst narrative points to Expensify as 39% overvalued relative to a US$1.13 fair value, the P/S ratio tells a different story. At 1.1x sales, Expensify trades well below the wider US Software industry at 3.3x, but slightly above its peer average of 1.0x and the fair ratio of 0.7x. That mix of discount and premium suggests valuation risk is now more about whether revenue and margins can justify even this modest multiple, or if the stock drifts closer to where peers and the fair ratio sit.

For a numbers first cross check of this pricing view, take a look at the See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

If this mix of optimism and caution on Expensify has you thinking, now is the time to review the numbers yourself, pressure test the assumptions before sentiment shifts again, and make sure you understand the 1 important warning sign.

Looking for more investment ideas beyond Expensify?

If Expensify has sharpened your focus on where capital goes next, do not stop here. Broaden your watchlist and give yourself more quality options to compare.

• Target potential value opportunities before the crowd by reviewing companies flagged in the 45 high quality undervalued stocks.
• Strengthen your defensive side by scanning the 66 resilient stocks with low risk scores for stocks with more resilient risk profiles.
• Spot earlier stage opportunities with solid fundamentals by checking the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.